Caribou Biosciences to Participate in Upcoming Investor Conferences
Provided By GlobeNewswire
Last update: Feb 18, 2025
BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences:
Read more at globenewswire.com
